| BFRI Stock | | | USD 0.87 0.11 14.47% |
This module uses fundamental data of Biofrontera to approximate its Piotroski F score. Biofrontera F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Biofrontera. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Biofrontera financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out
Biofrontera Altman Z Score,
Biofrontera Correlation,
Biofrontera Valuation, as well as analyze
Biofrontera Alpha and Beta and
Biofrontera Hype Analysis.
For more detail on how to invest in Biofrontera Stock please use our
How to Invest in Biofrontera guide.
As of now, Biofrontera's
Net Debt is decreasing as compared to previous years. The Biofrontera's current
Debt To Equity is estimated to increase to 1.01, while
Short and Long Term Debt Total is projected to decrease to under 5.1
M. As of now, Biofrontera's
Tangible Book Value Per Share is increasing as compared to previous years. The Biofrontera's current
Shareholders Equity Per Share is estimated to increase to 3.25, while
Price To Sales Ratio is projected to decrease to 0.12.
At this time, it appears that Biofrontera's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized
Piotroski F-Score model, we still consider it an effective method of
predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
| Change in Return on Assets | |
| Cash Flow Return on Assets | |
| Current Quality of Earnings (accrual) | |
| Long Term Debt Over Assets Change | Lower Leverage| Focus | |
| Change In Outstending Shares | |
Biofrontera Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Biofrontera is to make sure Biofrontera is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Biofrontera's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Biofrontera's financial numbers are properly reported.
Biofrontera F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical
financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Biofrontera's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Biofrontera in a much-optimized way.
Click cells to compare fundamentals
About Biofrontera Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled
Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
About Biofrontera Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biofrontera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biofrontera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Biofrontera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Biofrontera
offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock: Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost
the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share | Revenue Per Share | Quarterly Revenue Growth | Return On Assets | Return On Equity |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine
if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.